North America

Fri
15
Feb

Canopy Growth revenue soars, but so does its loss from operations

Canopy Growth Corp. says it generated $97.7 million of revenue in the three months ended Dec. 31, including its first sales of non-medical cannabis products, up from $21.7 million in the previous year’s fiscal third quarter.

The Ontario-based company — one of Canada’s largest cannabis producers — recorded a loss from operations for the quarter, but turned a net profit due to gains on the fair value of its assets and liabilities.

Loss from operations was $157.2 million, compared with a loss of $26 million a year earlier.

Net income attributable to shareholders, including net gains on the fair value of its assets, was $67.6 million or 22 cents per basic share, up from $1.6 million or one cent per basic share a year earlier.

Fri
15
Feb

Will the legalization of recreational marijuana be the death knell for medical cannabis?

Is the medical marijuana market dying?

Some people have argued that when recreational cannabis is legalized it will effectively push out the medical market, writes Calvin Hughes. Patients will forgo the hassle of getting a registered medical marijuana card and will instead frequent the local shops that require nothing more than a standard piece of government ID.

Fri
15
Feb

Will Aurora Cannabis continue bleeding money in 2019?

Aurora Cannabis (NYSE:ACB) lost a frightening amount of money during the last three months of 2018 and investors are justifiably concerned about more losses ahead. Despite posting heavy losses, management expects a sales explosion before the end of 2019 that could allow this giant Canadian cannabis producer to begin posting a profit by the end of the year.

Should investors brace for further losses ahead, or will Aurora Cannabis find a way to make ends meet before the end of 2019? Here's what you need to know to decide for yourself.

Fri
15
Feb

3 reasons marijuana stocks may go up in smoke

Valuations across the nascent legal marijuana space have been exploding over the last five years. The core reason is that the steady march toward legalization across the globe is widely expected to result in marijuana becoming one of the most valuable industries in the entire world within a decade's time.

Fri
15
Feb

Classing up cannabis: The science behind naming your canna-brand

What’s in a name? Cannabis called by any other name would smell just as dank, but that doesn’t mean it wouldn’t have any effect on how we perceive it. Names are important. We use names to distinguish objects and people—even brands. A great name can fill us with confidence and desire, and even make us more likely to purchase a product. A bad name, on the other hand, can completely turn us off from something that we may actually enjoy.

Fri
15
Feb

Children’s book aims to start the conversation about cannabis

A Southern California cannabis activist has written a book, titled What’s Growing in Grandma’s Garden, that she hopes will help parents talk with their kids about cannabis and is currently raising the funds necessary to publish the book and offer it to the public. Susan Soares, in an interview with High Times, said she has dedicated her life to educating people about cannabis.

“First and foremost, I’m an advocate for the cannabis plant,” says Soares. “It saved my life and completely turned my life around.”

Thu
14
Feb

Use of cannabis becomes more prevalent in cancer treatment

In the past few decades, medical institutions had begun to use cannabis a form of treatment, as a result of its multifarious therapeutic effects. Researchers have conducted years of studies in order to understand the plant and its effects further. Positive results have thus allowed the integration of cannabis into medical facilities, but it also helped propel the global legalization efforts. The active components in cannabis, THC and CBD, are linked to possessing beneficial effects on the body, which make them popular options for treatment. Currently, cannabis is predominately being used to treat mild to severe medical conditions such as chronic pain, cancer, epilepsy, and seizures.

Thu
14
Feb

Cannabis stocks climb ahead of congressional hearing on bank access

Cannabis shares were higher Wednesday ahead of a congressional hearing on the obstacles facing cannabis companies when it comes to opening and maintaining bank accounts.

A subcommittee of the Democratic-controlled House Financial Services Committee will meet to hear testimony on the topic at 2 p.m. Eastern time. For now, cannabis companies are unable to hold accounts at federally backed banks, because weed is still subject to a federal ban, another issue that is hampering the development of the sector in those states that have legalized cannabis for medical or recreational use.

Thu
14
Feb

What the heck is nebulizing? And is it the next big thing for consuming cannabis?

Anyone who knows someone with severe asthma might recognize a nebulizing machine. If not, the device is likely a complete mystery.

Thu
14
Feb

Parkinson’s Foundation will gather experts to study cannabis as disease therapy

These days, people with Parkinson’s disease tend to ask their doctors more questions about cannabis than any other subject; yet, few physicians have adequate answers for them.

So says a new survey announced by the Parkinson’s Foundation, which plans a conference on that subject next month in Denver.

The March 6-7 meeting will bring together about 40 top scientists, clinicians, physicians and marijuana industry executives, said James Beck, MD, the foundation’s chief scientific officer.

Pages

Subscribe to RSS - North America